Portola Pharmaceuticals   Print Page    Close Window

Corporate Profile

Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for... Read More

Stock Quote
NASDAQ PTLA (Common Stock)
$27.15 - 0.4
Stock chart for: PTLA.O.  Currently trading at $27.15 with a 52 week high of $56.70 and a 52 week low of $24.63.
09/24/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
Portola Pharmaceuticals, Inc. at Morgan Stanley 16th Annual Global Healthcare Conference
Wednesday, September 12, 2018 2:15 p.m. ET
LocationNew York, NY

Portola Pharmaceuticals, Inc. at Citi’s 13th Annual Biotech Conference
Thursday, September 6, 2018
LocationBoston, MA